Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired urine concent...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5231267?pdf=render |
| _version_ | 1818290395527774208 |
|---|---|
| author | Debbie Zittema Niek F Casteleijn Stephan J L Bakker Lianne S M Boesten A A Margreeth Duit Casper F M Franssen Carlo A J M Gaillard Ron T Gansevoort |
| author_facet | Debbie Zittema Niek F Casteleijn Stephan J L Bakker Lianne S M Boesten A A Margreeth Duit Casper F M Franssen Carlo A J M Gaillard Ron T Gansevoort |
| author_sort | Debbie Zittema |
| collection | DOAJ |
| description | Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.15 ADPKD (eGFR<60) patients and 15 age-, sex- and eGFR-matched controls with IgA nephropathy (IgAN), underwent a water deprivation test to determine maximal urine concentrating capacity. Plasma and urine osmolality, urine aquaporin-2 (AQP2) and plasma AVP and copeptin (a surrogate marker for AVP) were measured at baseline and after water deprivation (average 16 hours). In ADPKD patients, height adjusted total kidney volume (hTKV) was measured by MRI.Maximal achieved urine concentration was lower in ADPKD compared to IgAN controls (533±138 vs. 642±148 mOsm/kg, p = 0.046), with particularly a lower maximal achieved urine urea concentration (223±74 vs. 299±72 mmol/L, p = 0.008). After water deprivation, plasma osmolality was similar in both groups although change in plasma osmolality was more profound in ADPKD due to a lower baseline plasma osmolality in comparison to IgAN controls. Copeptin and AVP increased significantly in a similar way in both groups. AVP, copeptin and urine AQP2 were inversely associated with maximal urine concentrating in both groups.ADPKD patients have a more severely impaired maximal urine concentrating capacity with a lower maximal achieved urine urea concentration in comparison to IgAN controls with similar endogenous copeptin and AVP responses. |
| first_indexed | 2024-12-13T02:27:29Z |
| format | Article |
| id | doaj.art-f74228d340694098bc2244b7751511f3 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T02:27:29Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f74228d340694098bc2244b7751511f32022-12-22T00:02:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01121e016926310.1371/journal.pone.0169263Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.Debbie ZittemaNiek F CasteleijnStephan J L BakkerLianne S M BoestenA A Margreeth DuitCasper F M FranssenCarlo A J M GaillardRon T GansevoortAutosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.15 ADPKD (eGFR<60) patients and 15 age-, sex- and eGFR-matched controls with IgA nephropathy (IgAN), underwent a water deprivation test to determine maximal urine concentrating capacity. Plasma and urine osmolality, urine aquaporin-2 (AQP2) and plasma AVP and copeptin (a surrogate marker for AVP) were measured at baseline and after water deprivation (average 16 hours). In ADPKD patients, height adjusted total kidney volume (hTKV) was measured by MRI.Maximal achieved urine concentration was lower in ADPKD compared to IgAN controls (533±138 vs. 642±148 mOsm/kg, p = 0.046), with particularly a lower maximal achieved urine urea concentration (223±74 vs. 299±72 mmol/L, p = 0.008). After water deprivation, plasma osmolality was similar in both groups although change in plasma osmolality was more profound in ADPKD due to a lower baseline plasma osmolality in comparison to IgAN controls. Copeptin and AVP increased significantly in a similar way in both groups. AVP, copeptin and urine AQP2 were inversely associated with maximal urine concentrating in both groups.ADPKD patients have a more severely impaired maximal urine concentrating capacity with a lower maximal achieved urine urea concentration in comparison to IgAN controls with similar endogenous copeptin and AVP responses.http://europepmc.org/articles/PMC5231267?pdf=render |
| spellingShingle | Debbie Zittema Niek F Casteleijn Stephan J L Bakker Lianne S M Boesten A A Margreeth Duit Casper F M Franssen Carlo A J M Gaillard Ron T Gansevoort Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment. PLoS ONE |
| title | Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment. |
| title_full | Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment. |
| title_fullStr | Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment. |
| title_full_unstemmed | Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment. |
| title_short | Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment. |
| title_sort | urine concentrating capacity vasopressin and copeptin in adpkd and iga nephropathy patients with renal impairment |
| url | http://europepmc.org/articles/PMC5231267?pdf=render |
| work_keys_str_mv | AT debbiezittema urineconcentratingcapacityvasopressinandcopeptininadpkdandiganephropathypatientswithrenalimpairment AT niekfcasteleijn urineconcentratingcapacityvasopressinandcopeptininadpkdandiganephropathypatientswithrenalimpairment AT stephanjlbakker urineconcentratingcapacityvasopressinandcopeptininadpkdandiganephropathypatientswithrenalimpairment AT liannesmboesten urineconcentratingcapacityvasopressinandcopeptininadpkdandiganephropathypatientswithrenalimpairment AT aamargreethduit urineconcentratingcapacityvasopressinandcopeptininadpkdandiganephropathypatientswithrenalimpairment AT casperfmfranssen urineconcentratingcapacityvasopressinandcopeptininadpkdandiganephropathypatientswithrenalimpairment AT carloajmgaillard urineconcentratingcapacityvasopressinandcopeptininadpkdandiganephropathypatientswithrenalimpairment AT rontgansevoort urineconcentratingcapacityvasopressinandcopeptininadpkdandiganephropathypatientswithrenalimpairment |